Renal Angioplasty — Procedure Guide, Recovery & Risks | MyMedicPlus

Renal angioplasty (percutaneous transluminal renal angioplasty, PTRA) is a minimally invasive catheter-based procedure that uses a balloon catheter to dilate a narrowed (stenosed) renal artery, restoring adequate blood flow to the affected kidney. A metallic stent is typically deployed simultaneously to scaffold the artery open and maintain long-term patency — particularly for ostial atherosclerotic stenoses, which are prone to elastic recoil after balloon dilation alone.

The procedure is performed by interventional radiologists or vascular interventionalists under fluoroscopic (X-ray) guidance using contrast dye to visualise the renal arteries. It is the treatment of choice for two distinct disease entities that cause renal artery narrowing: fibromuscular dysplasia (FMD), a non-inflammatory, non-atherosclerotic structural disease of medium-sized arteries affecting predominantly young and middle-aged women; and atherosclerotic renal artery stenosis, which is caused by cholesterol plaque build-up at the renal artery origin (ostium) in older patients with established cardiovascular risk factors.

Renal artery stenosis affects an estimated 1–5% of all hypertensive patients and can cause renovascular hypertension — a secondary and potentially reversible cause of hypertension that is difficult to control with medications alone. It can also cause ischaemic nephropathy, where chronic under-perfusion of the kidney leads to progressive renal function decline. Renal angioplasty aims to improve blood pressure control, reduce the antihypertensive medication burden, and in selected patients, preserve or improve renal function.

Patient selection for renal angioplasty is critical and guided by the underlying aetiology, clinical presentation, and the findings of landmark randomised controlled trials that have shaped evidence-based indications.

Fibromuscular dysplasia (FMD): FMD is the primary indication where balloon angioplasty alone (without stenting) is highly effective. Current guidelines recommend PTRA for all symptomatic FMD patients with renovascular hypertension, as angioplasty achieves blood pressure cure (no antihypertensives required) in 30–40% and meaningful improvement in 50–75%. FMD is also treated when causing significant stenosis even in the absence of hypertension, to prevent progression and renal atrophy.

Atherosclerotic renal artery stenosis (ARAS): The evidence base for PTRA in ARAS is significantly more nuanced, reshaped by two landmark trials. The ASTRAL trial (2009) and the CORAL trial (2014) both demonstrated that renal artery stenting in addition to comprehensive medical therapy did not significantly improve renal function, blood pressure, or cardiovascular outcomes compared with optimal medical therapy alone in the overall ARAS population. Based on these findings, stenting is now reserved for carefully selected high-risk ARAS patients with: (a) haemodynamically significant stenosis (over 70% diameter reduction) in the main renal artery; (b) resistant hypertension despite 3 or more antihypertensive drugs at maximal tolerated doses; (c) flash pulmonary oedema (sudden pulmonary oedema in the context of known or suspected bilateral or single-kidney RAS); (d) rapidly progressive renal function decline (rising creatinine over weeks) without alternative explanation; or (e) bilateral renal artery stenosis causing significant ischaemic nephropathy.

Contraindications: Contraindications include chronic total occlusion with no viable kidney (kidney length under 7 cm, atrophic), contrast allergy without adequate pre-medication, severe uncorrectable coagulopathy, and life-limiting comorbidity making procedural benefit negligible.

Renal angioplasty is performed in an angiography suite by an interventional radiologist or cardiologist. Patients fast for 4–6 hours before the procedure. Renal function (creatinine, eGFR) is assessed pre-procedurally, and IV hydration is commenced before and after the procedure to reduce contrast-induced nephropathy risk, which is elevated in patients with pre-existing renal impairment.

Step 1 — Arterial access: The most common access route is the femoral artery in the groin, punctured under ultrasound guidance and secured with an introducer sheath (5–7 French). The radial artery at the wrist is an alternative access site, reducing access-site complications and allowing earlier mobilisation — particularly advantageous in patients on anticoagulation.

Step 2 — Diagnostic angiography: A flush aortogram is performed by injecting contrast into the abdominal aorta to visualise both renal arteries and the extent of stenosis. The degree of stenosis, location (ostial vs. non-ostial), length of the lesion, and presence of post-stenotic dilatation are characterised. Renal artery pressure measurements using a pressure wire (translesional gradient above 10 mmHg or fractional flow reserve below 0.80) confirm haemodynamic significance.

Step 3 — Lesion crossing and balloon dilation: A guiding catheter is positioned at the renal ostium. A 0.014-inch guidewire is carefully advanced across the stenosis under fluoroscopic guidance and positioned distally in the renal artery. A balloon catheter (4–6 mm diameter, 20 mm length for renal arteries) is advanced over the guidewire to the stenosis and inflated to 8–12 atmospheres pressure for 30–60 seconds, dilating the narrowed segment.

Step 4 — Stent deployment (for atherosclerotic ostial lesions): For ostial atherosclerotic stenoses — which recoil substantially after balloon dilation alone — a balloon-expandable bare-metal stent is pre-mounted on the balloon catheter and deployed across the lesion. The stent is post-dilated with a non-compliant balloon to ensure complete stent apposition against the vessel wall. Drug-coated stents and drug-eluting balloons are under investigation to reduce in-stent restenosis rates.

Step 5 — Completion angiography: A completion angiogram assesses the result, confirming less than 20% residual stenosis and absence of flow-limiting dissection. The guiding catheter, wire, and sheath are removed. Haemostasis is achieved at the access site with manual compression or an arterial closure device.

The outcomes of renal angioplasty differ substantially between the two underlying aetiologies, and patient selection determines whether meaningful clinical benefit is achievable.

Fibromuscular dysplasia: For FMD, balloon angioplasty (without stenting in most cases) achieves technical success in over 95% of procedures. Blood pressure cure (normotension without antihypertensives) is achieved in 30–40% of patients, with blood pressure improvement (reduction in drug number or dose) in an additional 50–60%. The best outcomes are seen in younger patients with shorter duration of hypertension, unilateral disease, and good pre-procedural kidney function. Angioplasty is significantly superior to medication alone and is the recommended first-line treatment for FMD-related renovascular hypertension in current ESC/ESH guidelines.

Atherosclerotic renal artery stenosis: For carefully selected high-risk ARAS patients not represented in the ASTRAL and CORAL trial populations (bilateral severe stenosis, flash pulmonary oedema, rapidly declining renal function), clinical series report blood pressure improvement in 40–60% and stabilisation or improvement of renal function in 30–50%. Technical success exceeds 95%, with primary patency of 70–80% at 3 years using bare-metal stents. In-stent restenosis occurs in 15–20% of cases at 2–3 years and can be re-treated with repeat balloon dilation.

Reduction in antihypertensive medication: Even in patients who are not cured of hypertension, successful PTRA may reduce the number of antihypertensive medications required, improving medication compliance and reducing side-effect burden — a meaningful quality-of-life benefit.

Renal angioplasty and stenting carries a well-characterised complication profile that must be weighed against expected clinical benefit.

Contrast-induced nephropathy (CIN): The most significant risk in patients with pre-existing renal impairment, occurring in 5–10% of cases without prophylaxis. Risk is reduced by minimising contrast volume, pre-hydration with IV saline or sodium bicarbonate (1 mL/kg/hour for 6–12 hours before and after), and holding nephrotoxic medications (NSAIDs, metformin) before the procedure.

Cholesterol embolisation: Distal embolisation of atheromatous debris during renal artery manipulation can cause acute kidney injury, blue toe syndrome, and livedo reticularis. This occurs in 1–2% of procedures and is more common with complex atherosclerotic disease. Embolic protection devices have been investigated but not proven to reduce outcomes.

Access site complications: Femoral haematoma (painful bruising at the access site) occurs in 2–5% of cases. Pseudoaneurysm formation requiring ultrasound-guided thrombin injection or surgical repair occurs in under 1%. Radial access has significantly lower access-site complication rates.

Renal artery dissection or rupture: Dissection occurs in under 1% of procedures and is usually managed with additional stent deployment. Rupture is very rare (under 0.5%) but can cause life-threatening retroperitoneal haemorrhage.

In-stent restenosis: Occurs in 15–20% of bare-metal stented renal arteries at 2–3 years, causing recurrent hypertension or renal function decline. Re-treatment with balloon angioplasty or cutting balloon technique achieves further improvement in most cases. Drug-eluting stents reduce but do not eliminate restenosis.

Recovery from renal angioplasty is rapid, with most patients mobilising and resuming normal diet on the day of or morning after the procedure.

Immediate post-procedure monitoring: Patients are observed in recovery for 4–6 hours after femoral access. Vital signs, access site, and urine output are monitored. Blood pressure may fluctuate significantly in the 24–48 hours after successful revascularisation — antihypertensive medications may need dose reduction to avoid hypotension. IV fluids continue for 4–12 hours post-procedure to promote contrast excretion and reduce nephropathy risk.

Hospital discharge (Day 1): Most patients are discharged the morning after the procedure. Femoral access site care instructions are provided. Patients are advised to avoid heavy lifting and strenuous activity for 3–5 days and to monitor the access site for signs of haematoma, bleeding, or pseudoaneurysm formation.

Blood pressure monitoring and medication adjustment: Blood pressure is measured daily at home for the first 4–6 weeks. Medications are adjusted by the referring physician as blood pressure responds to the procedure. Antihypertensive doses are often reduced significantly in FMD patients who achieve a good early blood pressure response. In ARAS patients, medication adjustment is more gradual.

Renal function monitoring: Serum creatinine and eGFR are checked at 48 hours (to detect CIN), then at 1, 3, and 12 months post-procedure. A rise in creatinine over baseline at 48 hours alerts the team to CIN and guides management. Improvement or stabilisation of renal function over the first 3–6 months is the primary indicator of procedural benefit in ischaemic nephropathy.

Stent surveillance: Duplex renal artery ultrasound at 3 months and annually monitors stent patency and peak systolic velocity ratios. In-stent restenosis identified on surveillance ultrasound prompts repeat angiography and treatment planning.